Zuellig Pharma
Concise Prescribing Info
Ertapenem Na
Moderate to severe infections caused by susceptible strains of microorganisms. Initial empiric therapy prior to identification of causative organisms in complicated intra-abdominal infections; complicated skin & skin structure infections including diabetic lower extremity & foot infections; community-acquired pneumonia; complicated UTI including pyelonephritis; acute pelvic infections including postpartum endomyometritis, septic abortion & postsurgical gynecologic infections; bacterial septicemia. Surgical prophylaxis of site infections following elective colorectal surgery.
Dosage/Direction for Use
Patient ≥13 yr 1 g once daily, 3 mth to 12 yr 15 mg/kg bid. Max: 1 g/day. Administer by IV infusion over 30 min or IM for 3-14 days. Adult Surgical prophylaxis of site infections following elective colorectal surgery 1 g as single IV dose given 1 hr prior to surgical incision. Patients w/ advanced renal insufficiency (CrCl ≤30 mL/min/1.73 m2) 500 mg daily. Patients on hemodialysis 500 mg w/in 6 hr prior to hemodialysis w/ a supplementary dose of 150 mg following hemodialysis.
Hypersensitivity to ertapenem Na, or other β-lactams. IM inj: Hypersensitivity to amide-type local anesth & in patients w/ severe shock or heart block.
Special Precautions
History of hypersensitivity to penicillins, cephalosporins, other β-lactams & other allergens. Discontinue immediately if an allergic reaction occurs. Patients w/ CNS disorders (eg, brain lesions or history of seizures) &/or compromised renal function. Concomitant use w/ valproic acid/divalproex Na. Consider supplemental anti-convulsant therapy in patients receiving valproic acid or divalproex Na in which Invanz administration is necessary. May result in overgrowth of non-susceptible organisms upon prolonged use. Pseudomembranous colitis especially in patients who present w/ diarrhea. Caution in administering IM to avoid inadvertent inj into a blood vessel. Pregnancy & lactation. Infant <3 mth.
Adverse Reactions
Adult: Headache; infused vein complication, phlebitis/thrombophlebitis; diarrhea, nausea, vomiting. Elevated ALT, AST, alkaline phosphatase & platelet count. Ped: Diarrhea, vomiting; infusion site erythema, pain, phlebitis & swelling; rash. Decreased neutrophil count.
Drug Interactions
Increased elimination t½ & systemic exposure w/ probenecid. Reduce conc of valproic acid.
MIMS Class
ATC Classification
J01DH03 - ertapenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections.
Invanz powd for inj 1 g
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in